Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.30)
# 3,302
Out of 4,825 analysts
97
Total ratings
36.71%
Success rate
-14.75%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Overweight | $3.25 → $2.5 | $0.76 | +229.95% | 4 | Apr 14, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $3.33 | +80.18% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $24.88 | +80.87% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $45.43 | +84.90% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $103.25 | +6.54% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $38.89 | -2.29% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $14.59 | +2.85% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $60.11 | -11.83% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.71 | +269.00% | 4 | Dec 13, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $57 → $70 | $40.64 | +72.24% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $1.79 | +12.04% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $2.04 | +833.66% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $5.01 | +279.24% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $1.72 | +774.64% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.34 | +996.49% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $4.75 | $2.49 | +90.76% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $29.00 | +24.14% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $7.64 | +423.90% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $8.55 | +75.44% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $11.23 | +211.80% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.87 | +417.24% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.36 | +2,105.88% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.59 | +1,161.83% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $0.87 | +1,046.13% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.41 | +1,176.60% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.41 | +1,673.05% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $4.62 | -62.12% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $24.33 | -17.80% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $0.83 | +80.98% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $0.42 | +2,298.08% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $4.04 | +766.34% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.19 | +4,942.02% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.90 | +520.69% | 3 | Apr 7, 2020 |
CytomX Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $3.25 → $2.5
Current: $0.76
Upside: +229.95%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.33
Upside: +80.18%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $24.88
Upside: +80.87%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $45.43
Upside: +84.90%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $103.25
Upside: +6.54%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $38.89
Upside: -2.29%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $14.59
Upside: +2.85%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $60.11
Upside: -11.83%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.71
Upside: +269.00%
Revolution Medicines
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $40.64
Upside: +72.24%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.79
Upside: +12.04%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $2.04
Upside: +833.66%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $5.01
Upside: +279.24%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $1.72
Upside: +774.64%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.34
Upside: +996.49%
Aug 19, 2024
Maintains: Neutral
Price Target: $6 → $4.75
Current: $2.49
Upside: +90.76%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $29.00
Upside: +24.14%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $7.64
Upside: +423.90%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $8.55
Upside: +75.44%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $11.23
Upside: +211.80%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.87
Upside: +417.24%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.36
Upside: +2,105.88%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.59
Upside: +1,161.83%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $0.87
Upside: +1,046.13%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $1.41
Upside: +1,176.60%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.41
Upside: +1,673.05%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $4.62
Upside: -62.12%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $24.33
Upside: -17.80%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $0.83
Upside: +80.98%
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.42
Upside: +2,298.08%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $4.04
Upside: +766.34%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.19
Upside: +4,942.02%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.90
Upside: +520.69%